---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-242460"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T10:41:11.722681+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioMarin reports phase 3 BMN 270 patient diagnosed with leukemia; initial tests find no link to therapy

## Summary
- BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.
- BMN 270 vector DNA in leukemic cells was negligible (<1 copy per 500 cells), suggesting no clonal expansion.
- No trial hold; all BMN 270 studies continue enrollment; DSMB agreed no modification needed.
- BioMarin remains on track to resubmit BMN 270 BLA to FDA by end of September 2022.

## SEC filing metadata
- accession: 0001193125-22-242460
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/0001193125-22-242460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/d306559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-242460
- JSON: https://secwatch.observer/filing/0001193125-22-242460.json
- Plain text: https://secwatch.observer/filing/0001193125-22-242460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.